Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYJQTF)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

6 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ligelizumab	DM103O8	Chronic idiopathic urticaria	EB00.1	Phase 3	[2]
MEMP1972A	DMUMCWS	Allergic rhinitis	CA08.0	Phase 2	[1]
AVP-13358	DM8CYJ1	Rhinitis	FA20	Phase 1	[3]
MEDI4212	DMBI4EN	Asthma	CA23	Phase 1	[4]
PF-06444752	DM9UZTO	Asthma	CA23	Phase 1	[5]
Xmab-7195	DME7IVL	Asthma	CA23	Phase 1	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Clinical Trial Drug(s)

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TAK-201	DM8S173	Allergy	4A80-4A85	Discontinued in Phase 2	[7]
IGE-026	DM16S98	Allergic rhinitis	CA08.0	Terminated	[8]
TEI-9874	DMXM3B4	Allergy	4A80-4A85	Terminated	[9]
------------------------------------------------------------------------------------

2 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D17.4	DMSON1P	Myasthenia gravis	8C6Y	Investigative	[10]
IGEL1.2	DMOU234	Allergy	4A80-4A85	Investigative	[10]
------------------------------------------------------------------------------------

References

1	International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
2	Clinical pipeline report, company report or official report of Novartis.
3	Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
4	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
5	ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
6	Clinical pipeline report, company report or official report of Xencor.
7	Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
8	IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.
9	Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
10	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.